SEC Form 4 · accession 0001562180-18-001429
Syndax Pharmaceuticals Inc · SNDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard P Shea
Officer — Chief Financial Officer
Period of report
Mar 1, 2018
Accepted (ET)
Mar 5, 2018 · 4:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001395937
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $9.40 | Mar 1, 2018 | A | 48,000 | A | — | Mar 1, 2028 | Common Stock | 48,000 | 48,000 | D |
Explanation of responses
- F1The stock option will vest in 48 successive equal monthly installments measured from February 8, 2018.